GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Prestige Consumer Healthcare Inc (NYSE:PBH) » Definitions » ROE %

Prestige Consumer Healthcare (Prestige Consumer Healthcare) ROE %

: 13.53% (As of Dec. 2023)
View and export this data going back to 2005. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Prestige Consumer Healthcare's annualized net income for the quarter that ended in Dec. 2023 was $212 Mil. Prestige Consumer Healthcare's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $1,568 Mil. Therefore, Prestige Consumer Healthcare's annualized ROE % for the quarter that ended in Dec. 2023 was 13.53%.

The historical rank and industry rank for Prestige Consumer Healthcare's ROE % or its related term are showing as below:

PBH' s ROE % Range Over the Past 10 Years
Min: -5.44   Med: 13.08   Max: 33.94
Current: -5.2

During the past 13 years, Prestige Consumer Healthcare's highest ROE % was 33.94%. The lowest was -5.44%. And the median was 13.08%.

PBH's ROE % is ranked worse than
67.6% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 4.42 vs PBH: -5.20

Prestige Consumer Healthcare ROE % Historical Data

The historical data trend for Prestige Consumer Healthcare's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prestige Consumer Healthcare Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.15 12.55 13.02 13.99 -5.44

Prestige Consumer Healthcare Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.57 -61.41 14.56 14.21 13.53

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prestige Consumer Healthcare ROE % Distribution

For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's ROE % distribution charts can be found below:

* The bar in red indicates where Prestige Consumer Healthcare's ROE % falls into.



Prestige Consumer Healthcare ROE % Calculation

Prestige Consumer Healthcare's annualized ROE % for the fiscal year that ended in Mar. 2023 is calculated as

ROE %=Net Income (A: Mar. 2023 )/( (Total Stockholders Equity (A: Mar. 2022 )+Total Stockholders Equity (A: Mar. 2023 ))/ count )
=-82.306/( (1577.611+1447.084)/ 2 )
=-82.306/1512.3475
=-5.44 %

Prestige Consumer Healthcare's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=212.184/( (1535.959+1600.577)/ 2 )
=212.184/1568.268
=13.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Prestige Consumer Healthcare  (NYSE:PBH) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=212.184/1568.268
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(212.184 / 1130.964)*(1130.964 / 3336.3135)*(3336.3135 / 1568.268)
=Net Margin %*Asset Turnover*Equity Multiplier
=18.76 %*0.339*2.1274
=ROA %*Equity Multiplier
=6.36 %*2.1274
=13.53 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=212.184/1568.268
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (212.184 / 278.3) * (278.3 / 347.328) * (347.328 / 1130.964) * (1130.964 / 3336.3135) * (3336.3135 / 1568.268)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7624 * 0.8013 * 30.71 % * 0.339 * 2.1274
=13.53 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Prestige Consumer Healthcare ROE % Related Terms

Thank you for viewing the detailed overview of Prestige Consumer Healthcare's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Prestige Consumer Healthcare (Prestige Consumer Healthcare) Business Description

Traded in Other Exchanges
Address
660 White Plains Road, Tarrytown, NY, USA, 10591
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Executives
Mary Beth Fritz officer: Senior VP Quality & Regulatory 660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Ronald M. Lombardi officer: Chief Executive Officer 660 WHITE PLAINS RD., TARRYTOWN NY 10591
James Darecca director C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Christine Sacco officer: Chief Financial Officer C/O SMART BALANCE, INC., 115 WEST CENTURY ROAD, SUITE 260, PARAMUS NJ 07652
Adel Mekhail other: EVP, Marketing & Sales 660 WHITE PLAINS RD., 2ND FL, TARRYTOWN NY 10591
William P'pool officer: See Remarks 2400 WEST LLOYD EXPRESSWAY, EVANSVILLE IL 47721
Celeste A. Clark director C/O ADVANCEPIERRE FOODS HOLDINGS, INC., 9987 CARVER ROAD, BLUE ASH OH 45242
Christopher J Coughlin director
Natale S Ricciardi director C/O MORRIS COMMUNICATIONS CORP, 725 BROAD ST., AUGUSTA GA 30903
James M Jenness director PO BOX 3599, BATTLECREEK MI 49016-3599
John E Byom director 660 WHITE PLAINS RD., TARRYTOWN NY 10591
Sheila Hopkins director C/O WARNACO INC, 90 PARK AVENUE, NEW YORK NY 10016
Dawn M. Zier director 600 OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034
Jeffrey Zerillo officer: Senior VP Operations 660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Timothy Connors officer: Chief Marketing Officer 660 WHITE PLAINS RD., SUITE 205, TARRYTOWN NY 10591

Prestige Consumer Healthcare (Prestige Consumer Healthcare) Headlines